Acquired microsatellite instability status and loss of HER2 positivity during treatment of gastro-esophageal junction adenocarcinoma

被引：0
|
作者：
Alexis, Lynn Gabrielle [1 ]
Dano, Helene [2 ]
Dekairelle, Anne-France [3 ]
Van Marcke, Cedric [1 ]
Van den Eynde, Marc [4 ,5 ]
机构：
[1] Univ Catholique Louvain UCLouvain, Inst Roi Albert II, Dept Med Oncol, Clin Univ St Luc, Brussels, Belgium
[2] Univ Catholique Louvain UCLouvain, Inst Roi Albert II, Dept Pathol, Clin Univ St Luc, Brussels, Belgium
[3] Univ Catholique Louvain UCLouvain, Inst Roi Albert II, Dept Genet, Clin Univ St Luc, Brussels, Belgium
[4] Univ Catholique Louvain UCLouvain, Inst Roi Albert II, Dept Med Oncol & Hepatogastroenterol, Clin Univ St Luc, Brussels, Belgium
[5] Clin Univ St Luc, Ave Hippocrate,10, B-1200 Brussels, Belgium
来源：
DIGESTIVE AND LIVER DISEASE | 2023年 / 55卷 / 03期
关键词：
HETEROGENEITY; EXPRESSION;
D O I：
10.1016/j.dld.2022.11.023
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：426 / 428
页数：3
相关论文
共 50 条
  • [41] HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
    Huang, Jun-Xing
    Zhao, Kun
    Lin, Mei
    Wang, Qi
    Xiao, Wei
    Lin, Mao-Song
    Yu, Hong
    Chen, Ping
    Qian, Rong-Yu
    ONCOLOGY LETTERS, 2013, 6 (01) : 13 - 18
  • [42] Change of HER2 status in metastatic esophageal adenocarcinoma: heterogeneity of the disease? Case report and review of literature
    Niu, Jiaxin
    Weber, Jeffrey
    Gelbspan, Deborah
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2012, 3 (04) : 358 - 361
  • [43] Characteristics, treatment (Tx) patterns and outcomes of patients with advanced/metastatic gastric cancer (GC) or gastro-esophageal junction (GEJ) adenocarcinoma previously treated with anti-HER2 therapy in an English national registry
    Starling, N.
    Zhang, L.
    Dunton, K.
    Struebing, A.
    Xiong, Y.
    Livings, C.
    Brannman, L.
    Beykloo, M. Yakhchi
    Mohamed, H.
    Trankov, N.
    Egger, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S883 - S883
  • [44] HER2 status in primary tumors and metastatic regional lymph nodes in patients with esophageal adenocarcinoma (EAC).
    Yoon, Harry H.
    Shi, Qian
    Sukov, William R.
    Sattler, Christopher A.
    Vaidya, Rakhee
    Wiktor, Anne E.
    Diasio, Robert B.
    Wu, Tsung-Teh
    Jenkins, Robert B.
    Sinicrope, Frank A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010
    Ilson, D.
    Moughan, J.
    Safran, H.
    Wigle, D.
    Depetrillo, T.
    Haddock, M.
    Hong, T.
    Leichman, L.
    Rajdev, L.
    Resnick, M.
    Kachnic, L.
    Seaward, S.
    Mamon, H.
    Pardo, D. Dian
    Anderson, C.
    Shen, X.
    Sharma, A.
    Katz, A.
    Salo, J.
    Leonard, K.
    Crane, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S235 - S235
  • [46] A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis
    DeVito, Nicholas C.
    Kelleher, Colm
    Strickland, Kyle C.
    Abbruzzese, James
    Anders, Carey
    Hanks, Brent A.
    Jia, Jingquan
    Mettu, Niharika B.
    Morse, Michael A.
    O'Neill, Margot
    Uronis, Hope
    Zafar, Yousuf
    Strickler, John H.
    AME CASE REPORTS, 2021, 5
  • [47] Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working
    Jouret-Mourin, A.
    Hoorens, A.
    De Hertogh, G.
    Vanderveken, J.
    Demetter, P.
    Van Cutsem, E.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2012, 75 (01) : 9 - 13
  • [48] Trastuzumab deruxtecan versus ramucirumab and paclitaxel as second-line therapy for patients with her2-positive gastric or gastro-esophageal junction adenocarcinoma: A propensity score matched comparison
    Verhoeven, R. H. A.
    Kuijper, S.
    Lordick, F.
    Slingerland, M.
    Qin, A.
    van Laarhoven, H. W. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S878 - S878
  • [49] Hormone receptor status might be a determinant for HER2 loss after HER2-targeted treatment in HER2 positive breast cancer patients
    Altundag, Kadri
    JOURNAL OF BUON, 2019, 24 (05): : 2206 - 2206
  • [50] Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma: More Is Better
    Huber, Aaron R.
    Buscaglia, Brandon
    Koltz, Brooke R.
    Henry, Jill
    McMahon, Loralee
    Guo, James
    Hicks, David G.
    Whitney-Miller, Christa L.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2019, 151 (05) : 461 - 468
12345